disease

Als

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Als: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

18426Connections
4Hypotheses
30Analyses
50Outgoing
50Incoming

Summary

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord. ALS leads to muscle weakness, atrophy, and eventual paralysis. Key genetic factors include mutations in SOD1, C9orf72, TDP-43, and FUS. Pathological mechanisms involve protein aggregation, RNA metabolism dysfunction, mitochondrial impairment, excitotoxicity, and neuroinflammation. The disease has a median survival of 3-5 years from symptom onset.

View on Wiki →

Disease Info
SynaptogenesisRelease of thrombospondins and other synaptogenic factors
Synaptic PruningParticipation in developmental synapse elimination
Neurotransmitter RecyclingConversion of glutamate to glutamine via glutamine synthetase
Associated GenesMAP6, HCN1, HCN4, HCN2, RASA1, EPHB4, HSPA1B, AGER
Therapeutic AgentsRiluzole, Arimoclomol
KG Connections9930 knowledge graph edges
DatabasesOMIMOrphanetClinicalTrialsPubMed

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Astrocytes in Amyotrophic Lateral Sclerosis

cell · 1490 words

cbs-psp-daily-action-plan

therapeutic · 30834 words

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

Clinical Management Guide for CBS/PSP

therapeutic · 15224 words

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

Pathway Diagram

graph TD
    subgraph Therapeutic["Therapeutic"]
        Als["Als"] -->|"therapeutic target"| Wnt["Wnt"]
        Als["Als"] -->|"therapeutic target"| Apoptosis["Apoptosis"]
        JUN["JUN"] -->|"therapeutic target"| Als["Als"]
    end
    subgraph Signaling["Signaling"]
        Als["Als"] -->|"activates"| Glycolysis["Glycolysis"]
        Als["Als"] -.->|"inhibits"| Mtor["Mtor"]
        Als["Als"] -->|"activates"| Complement["Complement"]
        Als["Als"] -->|"activates"| Phagocytosis["Phagocytosis"]
        Als["Als"] -->|"activates"| Nf__b["Nf-Kappab"]
        GAIN["GAIN"] -->|"activates"| Als["Als"]
        MTOR["MTOR"] -.->|"inhibits"| Als["Als"]
        APOE["APOE"] -.->|"inhibits"| Als["Als"]
        JUN_1["JUN"] -->|"activates"| Als["Als"]
    end
    subgraph Interactions["Interactions"]
        Als["Als"] -->|"interacts with"| Autophagy["Autophagy"]
        LC3["LC3"] -->|"interacts with"| Als["Als"]
    end
    subgraph Pathology["Pathology"]
        Als["Als"] -->|"associated with"| Neuroinflammation["Neuroinflammation"]
    end
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style Wnt fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Glycolysis fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Mtor fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Complement fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Phagocytosis fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Nf__b fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Neuroinflammation fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Apoptosis fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style JUN fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style GAIN fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style LC3 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style MTOR fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APOE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style JUN_1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (5123)

TargetRelationTypeStr
Wnttherapeutic_targetpathway1.00
Glycolysisactivatespathway1.00
Autophagyinteracts_withpathway1.00
Mtorinhibitspathway1.00
Complementactivatespathway1.00

Incoming (13303)

SourceRelationTypeStr
JUNtherapeutic_targetgene1.00
GAINactivatesgene1.00
LC3interacts_withgene1.00
MTORinhibitsgene1.00
APOEinhibitsgene1.00

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Stathmin-2 Splice Switching to Prevent Axonal Degeneration A 0.664 neurodegeneration RNA binding protein dysregulation across
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 0.601 neurodegeneration What are the mechanisms by which gut mic
PIKFYVE Inhibition Activates Aggregate Exocytosis via PI(3,5 0.559 neurodegeneration How does PIKFYVE inhibition activate unc
C9orf72-SMCR8-WDR41 Complex Dysfunction in C9-ALS Rescued by 0.537 neurodegeneration How does PIKFYVE inhibition activate unc

Mentioning Analyses (30)

Scientific analyses that reference this entity

How does SYNGAP1, a 'synaptic' protein, function in pre-synaptic radial glia cel

neurodevelopment | 2026-04-15 | 1 hypotheses Top: 0.576

Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondr

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.455

Does clusterin exacerbate or protect against neuronal death in neurodegeneration

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.548

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.604

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.606

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found